|The Viral Hepatitis Program acknowledges that community testing programs are in a unique position to identify people at risk for hepatitis C, to provide testing and linkage to care. The following information is provided to support efficient community testing for programs that use rapid hepatitis C tests.
There are 116,000 people estimated to be living with chronic hepatitis C in New York City; unfortunately, many are asymptomatic and unaware of their status. Hepatitis C is caused by a virus transmitted through blood that can lead to liver cancer and premature death. People born from 1945-1965, people who have injected drugs, people living with HIV, and men who have sex with men are at risk for hepatitis C and should be tested. Fortunately, hepatitis C can be treated and cured in 8-12 weeks with antiviral medications. However, a person can get infected with hepatitis C again after cure – if they are exposed to infected blood. Our goal is to remind programs that use rapid hepatitis C test kits of the recommended testing and reporting methods for hepatitis C.
Key factors to keep in mind:
There are two phases of hepatitis C infection:
Resources for Community Hepatitis C Testing
Contact Hep@health.nyc.gov or call our Hepatitis Navigation Warm-line (917) 890-0834 for assistance helping your patients get tested, treated and cured.
Diana Diaz Muñoz, Hep C Community Navigation Programs
Viral Hepatitis Program, NYC Health Department
CC: Nirah Johnson, Ann Winters
HepCX News, Publications, Reports, Annual Report, Hepatitis B & C
This report presents an overview of the New York City Health Department’s 2015 surveillance and research data on hepatitis B and C in NYC, as well as the Health Department’s programmatic activities to address these epidemics.
HepCX News, News, Medicaid, Pharmaceutical
YSDOH Drug Utilization Review Board meeting, the board voted to approve Viekira Pak as its preferred drug for persons chronically infected with HCV and enrolled in FFS Medicaid. Viekira Pak will be available for all chronically infected persons regardless of disease severity. Thi...
Advocacy, HepCX News, News, Hepatitis C, Medicaid, Open for Comment, Pharmaceutical
On February 26th, the New York State Drug Utilization Review Board will meet to review and recommend NYS Medicaid clinical criteria for Viekira Pak - the most recently approved Hepatitis C therapy - marketed by AbbVie.
Featured, Hep Free HOPE Team, HepCX News, Patient Education Materials, Public Education Committee, Drug Use, Hep C Task Force, Hepatitis C, Opioids, Video, Youth Programs
Watch and share this new video about prescription medication misuse and Hep C risk among young people in Staten Island.
HepCX News, News, Pharmaceutical
FDA Approves Viekira Pak to Treat Hep C A new hepatitis C medication, Viekira Pak, was approved today by the U.S. Food and Drug Administration (FDA). AbbVie, who markets the drug, has not immediately released the price of the new all-oral Hep C medication which will now rival Ha...
- Job | Hep C Linkage to Care Specialist @ Brightpoint Health October 2, 2019
- NYC Rapid Hep C Testing Guidance and Resources October 1, 2019
- Job | Hep C Peer Navigator @ New York Harm Reduction Educators September 27, 2019
- Funding | Request for Proposal: Targeted Approach to Jail-Based Programs and Services (Department of Correction) September 24, 2019
- Funding | Request for Proposal: Post-Incarceration Community-Based Transitional Services (Mayor’s Office of Criminal Justice) September 24, 2019
- Job | Community Health Worker/Peer Navigator @ STAR Program SUNY Downstate September 20, 2019
- Job | Hepatitis Program Assistant (CUNY Master students ONLY) @ NYC Health Department September 20, 2019